Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Sabin-IPV Replacement Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects aged from 60 days to 89 days old at the date of recruitment;~* with informed consent signed by parent(s) or guardians;~* parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions;~* subjects did not receive any vaccines within 14 days;~* axillary temperature ≤37.0℃~Exclusion Criteria:~* allergic to any ingredient of vaccine or with allergy history to any vaccine;~* acute febrile disease or infectious disease;~* serious chronic diseases;~* any other factor that makes the investigator determines the subject is unsuitable for this study;

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- group 1 (Type: EXPERIMENTAL): 180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
- group 2 (Type: ACTIVE_COMPARATOR): 180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV

Based on this trial design, predict the completion outcome and termination type (if applicable).